IgM myeloma: A multicenter retrospective study of 134 patients

Autoři	CASTILLO J.J. JURCZYSZYN A. BROŽOVÁ Lucie CRUSOE E. CZEPIEL J. DAVILA J. DISPENZIERI A. EVEILLARD M. FIALA M.A. GHOBRIAL I.M. GOZZETTI A. GUSTINE J.N. HAJEK R. HUNGRIA V. JARKOVSKÝ Jiří JAYABALAN D. LAUBACH J.P. LEWICKA B. MAISNAR V. MANASANCH E.E. MOREAU P. MORGAN E.A. NAHI H. NIESVIZKY R. PABA-PRADA C. PIKA T. POUR Luděk REAGAN J.L. RICHARDSON P.G. SHAH J. SPICKA I. VIJ R. WASZCZUK-GAJDA A. GERTZ M.A.
Rok publikování	2017
Druh	Článek v odborném periodiku
Časopis / Zdroj	American Journal of Hematology
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
Doi	http://dx.doi.org/10.1002/ajh.24753
Obor	Onkologie a hematologie
Klíčová slova	IgM myeloma
Popis	IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10% marrow involvement by monoclonal plasma cells, presence of an IgM monoclonal paraproteinemia of any size, and anemia, renal dysfunction, hypercalcemia, lytic lesions and/or t(11;14) identified by FISH. A total of 134 patients from 20 centers were included in this analysis. The median age at diagnosis was 65.5 years with a male predominance (68%). Anemia, renal dysfunction, elevated calcium and skeletal lytic lesions were found in 37, 43, 19, and 70%, respectively. The median serum IgM level was 2,895 mgdL(-1) with 19% of patients presenting with levels >6,000 mgdL(-1). International Staging System (ISS) stages 1, 2, and 3 were seen in 40 (33%), 54 (44%), and 29 (24%) of patients, respectively. The malignant cells expressed CD20 (58%) and cyclin D1 (67%), and t(11;14) was the most common cytogenetic finding (39%). The median overall survival (OS) was 61 months. Higher ISS score was associated with worse survival (P=0.02). Patients with IgM myeloma present with similar characteristics and outcomes as patients with more common myeloma subtypes.